P-0150 - Primary anorectal melanoma: report of 21 cases and literature review

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Melanoma and other Skin Tumours
Presenter Tarik Mahfoud
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors T. Mahfoud
  • Department of Medical Oncology, Military Hospital Mohammed V, Rabat/MA



Primary anorectal melanoma is a rare and aggressive disease. It accounts for 0.5% of all rectal tumors. They are very aggressive tumors with poor prognosis. The aim of this study is to report the clinical and evolutionary profile and therapeutic approach of these tumors.


A retrospective study of 21 patients with primary anorectal melanoma diagnosed between January 1998 and November 2009 was performed. The signs and symptoms, diagnostic study, and surgical and medical treatments were analyzed.


The average age was 54 years. Sex ratio was 14 men/ 7 women. The most common symptom was rectal bleeding (100% of cases) and rectal pain (90% of cases). According to Slingluff classification, 6 patients had stage I (localized tumor), 5 cases had stage II (regional nodes metastasis), and 10 cases had stage III (distant metastasis). Seven patients have radical surgery. Only two patients received adjuvant immunotherapy. Eleven patients received palliative chemotherapy based on dacarbazine or cisplatinum. The median survival was 8.6 months.


Primary anorectal melanoma is a rare disease. Prognosis is still very poor. However, radical resection when it's possible can improve the prognosis with some experiences of long-term survival. The role of adjuvant immunotherapy is not well determined. Palliative chemotherapy improved prognostic for advanced disease.